| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79a8e7878654e53a46fd2cb4c8075053 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2016-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c04804aab2d221f4de04e558467dd21c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64bc21def1fe6fdceca4302bc48b6f67 |
| publicationDate |
2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180021364-A |
| titleOfInvention |
Hepatic artery injection of CAR-T cells |
| abstract |
Compositions and methods for the treatment of liver metastases in a subject are disclosed herein. The method involves hepatic artery injection (HAI) of a chimeric antigen receptor-modified T cell (CAR-T), which is very specific for tumor antigens, such as cancerous embryonic antigen (CEA). The HAI method is optimized to maximize exposure of transformed cells to metastatic cells while minimizing exposure to healthy cells. The method comprises simultaneous administration of a second therapeutic agent, such as IL-2. |
| priorityDate |
2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |